Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC

Open-label, single-arm, prospective multicenter phase II clinical trial to determine the efficacy of immunotherapy with durvalumab concomitant with radiochemotherapy, followed by durvalumab maintenance therapy in combination with stereotactic radiotherapy in extensive stage SCLC

Trial Details

NCT ID
NCT06223711
Phase
PHASE2
Sponsor
Universität des Saarlandes
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Thoracic Radiochemotherapy
  • durvalumab
  • Stereotactic radiotherapy of further tumor locations
  • Chemotherapy
Locations (sample)
  • Augsburg, Bavaria, Germany|48.37154,10.89851
  • Erlangen, Bavaria, Germany|49.59099,11.00783
  • Regensburg, Bavaria, Germany|49.01513,12.10161
  • Mönchengladbach, North Rhine-Westphalia, Germany|51.18539,6.44172
  • Homburg, Saarland, Germany|49.32637,7.33867

Key Eligibility Criteria

  • For inclusion in the study patients must fulfill all of the following criteria:
  • Histologically confirmed first diagnosis of ES-SCLC according to the Veterans Administration Lung Study Group (VALG) Staging System for SCLC1 (dise…
  • Oligometastatic disease defined as follows:
  • Primary tumor with or without mediastinal or supraclavicular lymph node metastases (counts as one lesion if it can be treated within one radiation …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →